Discovered differences in pancreatic cancer cells offer new hope for immunotherapy
Sist anmeldt: 14.06.2024
Alt iLive-innhold blir gjennomgått med medisin eller faktisk kontrollert for å sikre så mye faktuell nøyaktighet som mulig.
Vi har strenge retningslinjer for innkjøp og kun kobling til anerkjente medieområder, akademiske forskningsinstitusjoner og, når det er mulig, medisinsk peer-evaluerte studier. Merk at tallene i parenteser ([1], [2], etc.) er klikkbare koblinger til disse studiene.
Hvis du føler at noe av innholdet vårt er unøyaktig, utdatert eller ellers tvilsomt, velg det og trykk Ctrl + Enter.
A new study has found that pancreatic cancer cells vary depending on their location in the organ, providing new information about tumors and could lead to more targeted treatments.
Pancreatic ductal adenocarcinoma (PDAC) is an aggressive type of cancer, and the number of diagnoses has increased significantly over the past decade. It is currently the seventh leading cause of cancer deaths among men and women worldwide and is expected to become the third leading cause of cancer-related deaths worldwide by 2030. This increase is due to several factors, such as an increase in the incidence of obesity and diabetes.
Houston Methodist's Chief of Gastrointestinal Medical Oncology, Dr. Maen Abdelrahim, pioneered and conceptualized the article entitled "Comparative Molecular Profiling of Head Versus Body and Tail Pancreatic Ductal Adenocarcinoma," published in npj Precision Oncology. The research team found that the anatomical location of the pancreatic tumor is an important factor influencing the results of systematic therapeutic interventions.
Abdelrahim and colleagues hypothesized that there is a difference in the microenvironment of tumors in the head of the pancreas compared to the body and tail, especially with regard to immune therapy receptors found in each of these parts pancreas.
"By focusing on the biology around the tumor and considering its location on the pancreas, we can better evaluate our treatment options," Abdelrahim said. "Rather than treating patients under the umbrella term of pancreatic malignancy, moving to a model based on tumor location could significantly change how clinicians develop preliminary treatment plans."
The team hopes this discovery will help clinicians develop more specific treatment plans and improve patient outcomes.